Literature DB >> 23529042

Growth hormone in health and disease: Long-term GH therapy--benefits and unanswered questions.

David Clemmons.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23529042     DOI： 10.1038/nrendo.2013.68

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Does pituitary radiotherapy increase the risk of stroke and, if so, what preventative actions should be taken?

Authors:  John Ayuk
Journal:  Clin Endocrinol (Oxf)       Date:  2012-03       Impact factor: 3.478

2.  Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis.

Authors:  Roger Abs; Ulla Feldt-Rasmussen; Anders F Mattsson; John P Monson; Bengt-Ake Bengtsson; Miklós I Góth; Patrick Wilton; Maria Koltowska-Häggström
Journal:  Eur J Endocrinol       Date:  2006-07       Impact factor: 6.664

3.  Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure.

Authors:  G Johannsson; P Mårin; L Lönn; M Ottosson; K Stenlöf; P Björntorp; L Sjöström; B A Bengtsson
Journal:  J Clin Endocrinol Metab       Date:  1997-03       Impact factor: 5.958

4.  Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status--3-year results from the HypoCCS Database.

Authors:  Andrea F Attanasio; Peter C Bates; Ken K Y Ho; Susan M Webb; Richard J Ross; Christian J Strasburger; Roger Bouillon; Brenda Crowe; Keith Selander; Domenico Valle; Steven W J Lamberts
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

Review 5.  Mortality in patients with pituitary disease.

Authors:  Mark Sherlock; John Ayuk; Jeremy W Tomlinson; Andrew A Toogood; Aurora Aragon-Alonso; Michael C Sheppard; Andrew S Bates; Paul M Stewart
Journal:  Endocr Rev       Date:  2010-01-19       Impact factor: 19.871

6.  Factors influencing the desire for long-term growth hormone replacement in adults.

Authors:  S J Holmes; S M Shalet
Journal:  Clin Endocrinol (Oxf)       Date:  1995-08       Impact factor: 3.478

7.  Occurrence of impaired fasting glucose in GH-deficient adults receiving GH replacement compared with untreated subjects.

Authors:  Whitney W Woodmansee; Mark L Hartman; Steven W J Lamberts; Anthony J Zagar; David R Clemmons
Journal:  Clin Endocrinol (Oxf)       Date:  2009-05-04       Impact factor: 3.478

Review 8.  Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects.

Authors:  Niels Møller; Jens Otto Lunde Jørgensen
Journal:  Endocr Rev       Date:  2009-02-24       Impact factor: 19.871

9.  Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency.

Authors:  Mariam Elbornsson; Galina Götherström; Ingvar Bosæus; Bengt-Åke Bengtsson; Gudmundur Johannsson; Johan Svensson
Journal:  Eur J Endocrinol       Date:  2012-02-08       Impact factor: 6.664

10.  Fifteen years of GH replacement improves body composition and cardiovascular risk factors.

Authors:  Mariam Elbornsson; Galina Götherström; Ingvar Bosæus; Bengt-Åke Bengtsson; Gudmundur Johannsson; Johan Svensson
Journal:  Eur J Endocrinol       Date:  2013-04-15       Impact factor: 6.664
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.